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Background: Vein wall ﬁbrotic injury following deep venous thrombosis (VT) is associated with elevated matrix metal-
loproteinases (MMPs). Whether and by what mechanism MMP2 contributes to vein wall remodeling after VT is
unknown.
Methods: Stasis VT was produced by ligation of the inferior vena cava and tissue was harvested at 2, 8, and 21 days in
MMP2 -/- and genetic wild type (WT) mice. Tissue analysis by immunohistochemistry, enzyme-linked immunosorbent
assay, real-time polymerase chain reaction, and zymography was performed.
Results: Thrombus resolution was less at 8 days in MMP2 -/- compared with WT, evidenced by a 51% increase in VT size
(P < .01), and threefold fewer von Willebrand’s factor positive channels (P < .05). In MMP2 -/- mice, the main
phenotypic ﬁbrotic differences occurred at 8 days post-VT, with signiﬁcantly less vein wall collagen content (P[ .013),
fourfold lower procollagen III gene expression (P < .01), but no difference in procollagen I compared with WT.
Decreased inﬂammation in MMP2 -/- vein walls was suggested by w threefold reduced TNFa and IL-1b at 2 days and
8 days post-VT (P < .05). A fourfold increase in vein wall monocytes (P [ .03) with threefold decreased apoptosis
(P < .05), but no difference in cellular proliferation at 8 days was found in MMP2 -/- compared with WT. As increased
compensatory MMP9 activity was observed in the MMP2 -/-mice, MMP2/9 double null mice had thrombus induced
with VT harvest at 8 days. Consistently, twofold larger VT, a threefold decrease in vein wall collagen, and a threefold
increase in monocytes were found (all P < .05). Similar ﬁndings were observed in MMP9 -/- mice administered an
exogenous MMP2 inhibitor.
Conclusions: In stasis VT, deletion of MMP2 was associated with less midterm vein wall ﬁbrosis and inﬂammation, despite
an increase in monocytes. Consideration that VT resolution was impaired with MMP2 (and MMP2/9) deletion suggests
direct inhibition will likely also require anticoagulant therapy. (J Vasc Surg 2013;58:1375-84.)
Clinical Relevance: Post-thrombotic syndrome has no direct therapies and causes signiﬁcant morbidity. Anticoagulation
limits thrombosis but does not clinically impact directly the vein wall response to injury as well as has bleeding risks. In
this experimental study, we show that matrix metalloproteinase 2 genetic deletion lessens ﬁbrotic injury and inﬂammation
at the midterm timepoint, yet is also important for thrombus resolution. Future therapies that positively impact vein wall
remodeling will need to account for how the thrombus responds as well.Deep venous thrombosis (DVT) is a signiﬁcant health
care problem in this country, with over 250,000 patients
affected yearly, although these ﬁgures may be conservative.1
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://dx.doi.org/10.1016/j.jvs.2012.11.088sequelae of post-thrombotic syndrome (PTS), characterized
by leg pain, sensations of heaviness, limb edema, discolor-
ation, and occasionally ulceration.2 The end result after
DVT is the conversion of a compliant, thin walled vein
with functional valves to a thick walled vessel, often with
nonfunctioning valves.3 The physiological result of damaged
veins is pooling of blood in the dependent extremities,
producing venous hypertension, ﬂuid transudation, edema,
and potentially ulceration.
Despite effective anticoagulant therapy treatments for
DVT, there are no therapies that speciﬁcally target the
PTS remodeling processes.4 Although surgical and inter-
ventional therapy may be beneﬁcial for selected patients,
treatment for PTS is mainly supportive, consisting of
compression and wound care. Although largely effective,
compression does not correct the fundamental changes
that occur in the venous system and compliance with
such ongoing regimens is often difﬁcult.
Rodent studies have suggested that the mechanism
and duration of thrombosis affects the magnitude of1375
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thrombus is more damaging than a nonstatic thrombus and
negatively affects collagen structure and venous compli-
ance.5,6 In addition to the intense inﬂammatory reaction
seen following DVT, there is a phenotypic alteration in the
extracellular matrix, associated with activation of matrix
metalloproteinases (MMPs), including MMP2 and 9.6-9
Of these, MMP2 is most signiﬁcantly elevated in the vein
wall after stasis venous thrombosis (VT) at the mid and later
timepoints,6 and is when PTS occurs in humans. Although
broad MMP inhibition may decrease some measures of
injury,10,11 their speciﬁc role has not been deﬁned in the
vein wall after VT. The additive effects of MMP2/9 genetic
deletions have been highlighted with experimental lung
injury.12 Moreover, recent studies suggest certain
biomarkers may be predictive of PTS well as associated
with DVT resolution in humans, including MMPs.4,13
We hypothesized that abrogation of matrix remodeling
via genetic deletion of MMP2 and combined MMP2/9
would lessen the damage seen in the vein wall following
stasis VT.
METHODS
Animal model. Male mice 6 to 8 weeks old, MMP2 -/-
(kindly donated by Dr Eric Choi) and C57BL/6 wild type
(WT) were used for the experiments. With all surgical
procedures, the mice were anesthetized using inhalational
isoﬂurane and O2, and continuously monitored. Animal
studies were approved by the University of Michigan
Committee on Use and Care of Animals.
Experimental VT was created in the mouse using
infrarenal inferior vena cava (IVC) ligation as previously
described.6,14-16 Brieﬂy, mice were anesthetized, and under-
went midline laparotomy. The IVC was ligated with a 7-0
prolene suture immediately below the renal veins. Back
(lumbar) branches were ablated with cautery, and all visible
side branches were interrupted with 7-0 prolene suture.
Mice were sacriﬁced on days 2, 8, and 21 days post-
ligation. At sacriﬁce, the thrombosed IVC segment was
carefully dissected and removed for formalin ﬁxation and
parafﬁn embedding (for histology/immunohistochemistry)
or immediately snap frozen (70C) to preserve for tissue
processing.
At days 2 and 8, the thrombus was separated from the
vein wall for processing; however, at 21days, the thrombus
and vein wall form a segment of scar tissue, which cannot
be separated without tissue disruption, and those segments
were processed together. In other experiments, a speciﬁc
MMP2 inhibitor17,18 (OA-Hy; EMD Biosciences, Gibbs-
town, NJ) 6.25 mcg per mouse in 1 mg/mL diluted
dimethyl sulfoxide or the vehicle, was administered intraper-
itoneal to MMP9 -/- mice immediately after IVC ligation
and at 4 days post-VT, with harvest at 8 days. Separate
C57BL/6 MMP9 -/- were crossed with C57BL/6
MMP-2 -/- mice to generate MMP2 -/- double null mice.
Sodium dodecyl sulfate polyacrylamide gel electro-
phoresis gelatin zymography. Activity of the gelatinases
(MMP2 and MMP9, active and latent forms) wasdetermined by gelatin zymography on 10% sodium dodecyl
sulfate-polyacrylamide gels, as previously described.5,15,18
Activity was visualized as light staining bands on a dark
background and normalized to the total amount of protein
present in each sample as previously described.
Histology/immunohistochemical/apoptosis/collagen
staining. Tissue samples were formalin ﬁxed, parafﬁn
embedded, and cut into 5 mm sections as described.14,15
Nonspeciﬁc sites were blocked with normal serum, and
sections were incubated with primary antibodies to Mac2
(1:200; Cedarlane Laboratories, Burlington, NC), von
Willebrand’s factor (vWF; 1:500; Abcam, Cambridge,
Mass), and Ki-67 (1:100; Abcam). A species-speciﬁc ABC
peroxidase kit for either rabbit or rat (Vector Laboratories
Inc, Burlingame, Calif) was used according to the manu-
facturer’s instructions for the corresponding secondary
antibody and subsequent steps. The slides were counter-
stained with hematoxylin. In a blinded fashion, positive cells
in ﬁve high power ﬁelds (1000) radially around the IVC
were counted and totaled.
The presence of apoptotic cell death was assessed in the
vein wall by using a commercially available kit to determine
the presence of characteristic DNA breaks by the TUNEL
method (Trevigen Inc, Gaithersburg, Md).
Picrosirius red staining to quantify collagen content
was performed as described.19,20 These sections were
then analyzed in crossed-plane polarized light from
a monochromatic source to assess cross-linked collagen.
Two images for each were obtained using a Zeiss Axio
M1 scope and Zeiss AxioVision software (Carl Zeiss Micro-
imaging GmbH, Göttingen, Germany) at 0 and 90 degrees
to the plane of polarization, to capture the birefringence of
ﬁbers extinguished in one direction. The images were
analyzed blindly utilizing NIH Image J software. The
area corresponding to the vein wall was selected as
a region-of-interest, and then the image underwent
threshold segmentation to differentiate collagen from other
(mainly cellular and empty space) components of the vein
wall. A vein wall collagen score was assigned by the formula
[(% birefringent area)  (measured vein wall area)]/(total
specimen area).21
To account for noncollagen vein wall changes, intimal
thickness scoring was assessed from H and E sections as
described.22 A consistent midsection thrombosed IVC
segment was used for all histologic analysis.16,18,23
Antigen analysis by enzyme-linked immunosorbent
assay. Vein wall tissue was homogenized, subjected to
ultrasonic sonication, followed by centrifugation samples
centrifuged at 10,000 g for 5 minutes, and the superna-
tant was collected for analysis. Quantiﬁcation of the
analyzed antigens was normalized to the total protein
present in the sample, using a modiﬁed Bradford assay
(Pierce Inc, Rockford, Ill). Enzyme-linked immunosor-
bent assay for mouse tumor necrosis factor-alpha (TNFa),
interleukin-1 beta (IL-1b), transforming growth factor
beta (TGFb), and monocyte chemotactic protein-1 (MCP-
1) was performed according to manufacturer’s instructions
(all from R and D, Minneapolis, Minn).5,14
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The levels of expression for genes of interest were deter-
mined by isolating total RNA via Trizol extraction as previ-
ously described.15,16 Then, the RNA underwent reverse
transcription. The complementary DNA was then sub-
jected to a real-time reverse transcriptase reaction using
Taq polymerase (Promega, Madison, Wisc) in a Smart-
Cycler quantitative polymerase chain reaction system
(Cepheid, Sunnyvale, Calif). SYBR green intercalating dye
(Roche, Indianapolis, Ind) was used to monitor levels of
complementary DNA ampliﬁcation for each gene. b-actin
was used as an internal control for reference in each sample.
The sequence numbers were: Col1a2 - RefSeq#
NM_007743.3; Col3a1 - RefSeq# NM_009930.2; tro-
poelastin - RefSeq # NM_0036834.3; beta Actin - RefSeq#
NM_007393.3.
Statistical analysis. All data are presented as mean 6
SE. Comparisons were made using an unpaired Student
t-test or analysis of variance with Dunnett or Bonferroni
multiple comparison tests as appropriate, using GraphPad
Prism v. 4.0 for Windows (GraphPad Software, San Diego,
Calif).RESULTS
MMP2 deletion impairs midpoint VT resolution.
The weight:length ratio of a resolving thrombus provides
a simple but reliable measure of thrombus resolution.6,14-16
Given that the inﬂammatory response is crucial for
resolving VT, interventions that affect inﬂammation might
impair thrombus resolution. At 8 days, MMP2 -/- mice
had a 51% increase in VT size compared with WT
(n ¼ 15-20; P < .001) (Fig 1, A). These data are consistent
with prior investigation of MMP2 activity in VT resolution
between 4 and 8 days and this timepoint was not
repeated.15,18 No differences were observed in VT size at
2 days (n ¼ 12-14; P ¼ .6) or 21 days (14 6 1 vs 17 6
2 mg/cm; n ¼ 20-22; P ¼ .16) in MMP2 -/- mice
compared with WT controls.
Resolution of a VT is conferred in part by development of
vWF þ vascular channels in the thrombus.14,16 Correlating
with impaired thrombus resolution in MMP2 -/- mice at
8 days were threefold less vWF þ channels (n ¼ 5;
P ¼ .025) (Fig 1, B-D).
Post-thrombotic vein wall collagen metabolism is
altered in MMP2 -/- mice. The 8- and 21-day timepoints
were chosen to evaluate the loss of MMP2 as these mimic
the post-thrombotic syndrome time frame, with a signiﬁ-
cantly thicker and collagen dense vein wall, as well as when
MMP2 activity is present.5,6 Vein wall collagen as assessed
by Picosirius red increases over time following thrombosis
(Supplementary Fig 1, online only). The collagen content
was w35% less in the MMP2 -/- mice compared with the
WT (n ¼ 4-5; P ¼ .013) (Fig 2, A-C), with no differences
in intimal thickness at 8 days (Supplementary Fig 2, online
only). No difference in collagen was found at 21 days in
MMP2 -/- compared with WT (6.5 6 1.3 vs 6.0 6 1.4%
vein wall section; n ¼ 4-5; P ¼ .9).Experimental VT is associated with an upregulation of
procollagen messenger RNA in the vein wall,13 speciﬁcally
procollagen I and procollagen III. This was analyzed at 2
and 8 days. In the MMP2 -/- mice, procollagen I gene
expression was not signiﬁcantly different at 2 or 8 days
(2-day comparison P ¼ .26; 8-day comparison P ¼ .55;
n ¼ 4-5 each group) (Fig 2, D). Procollagen III gene
expression was decreased wfourfold in the MMP2 -/-
mice compared with the WT at 8 days (n ¼ 5; P < .01),
with no differences at 2 days (not shown) (Fig 2, E). As
a precursor to elastin, tropoelastin gene expression was
not altered at 2 days, but was decreased w 2.5-fold at 8
days in MMP2 -/- compared with WT mice (Fig 2, F).
Vein wall inﬂammation and apoptosis is decreased
in MMP2 -/- mice at 8 days. Inﬂammatory mediators are
present in the thrombus and vein wall after VT, including
TNFa, IL-1b, and MCP-1.5,14,15 In the MMP2 -/-
mice, TGFb protein levels were not signiﬁcantly different at
8 days (3.9 6 0.9 vs 2.5 6 0.08 ng/mg protein; n ¼ 5;
P ¼ NS), compared with WT. TNFa was reduced three- to
fourfold at 2 and 8 days in the MMP2 -/- mice compared
with WT (n ¼ 4-5; P ¼ .03) (Fig 3, A). IL-1b was reduced
2.5-fold in the MMP2 -/- mice compared with WT at 2
days (n ¼ 4-5; P ¼ .01) (Fig 3, B) but not at 8 days (5176
300 vs 361 6 71 pg/mg protein; n ¼ 5; P > .05). No
signiﬁcant differences were found in MCP-1 levels at 2 or
8 days (not shown). The MMP2 -/- mice hadwthreefold
reciprocally increased MMP9 activity by zymography
(n ¼ 5; P # .01) at day 8 only (Fig 3, C).
Since MMP2 is both produced by leukocytes in the
early inﬂammatory response, and in part mediates their
migration across collagen-rich matrices such as the base-
ment membrane,24 we investigated whether the loss of
MMP2 would have an effect on the number of inﬂamma-
tory cells present in the vein wall. In the MMP2 -/- vein
wall, monocytes were increased wfourfold in MMP2 -/-
mice compared with WT (n ¼ 4-5; P ¼ .03) (Fig 3, D
and Supplementary Fig 3, online only).
Medial cellular proliferation and apoptosis contributes
to postvascular injury ﬁbrosis.25,26 To evaluate for the
contribution of cellular proliferation, Ki67 antigen staining
was evaluated in the medial vein layer.5 Ki67 positive cells
staining showed no signiﬁcant difference in MMP2 -/-
compared with WT sections (7 6 1 vs 5 6 1 cells/5hpf;
n ¼ 6-7; P ¼ .3). However, fewer apoptotic nuclei by
TUNEL þ staining were present in the MMP2 -/- mice,
with wfourfold less apoptosis at 8 days compared with
WT (n ¼ 6; P ¼ .045) (Fig 3, E-G).
Combined MMP2 and MMP9 deletion on vein
wall response. For the previous experiments with the
single MMP2 deleted mice, we found reciprocally elevated
MMP9 activity at 8 days. This was also the point where
the collagen metabolism was affected most signiﬁcantly by
the MMP2 deletion. Thus, we evaluated MMP2 -/-
MMP9 -/- double null mice as well as MMP9 -/- mice
given a speciﬁc MMP2 inhibitor.18 Stasis VT was induced
with harvest at 8 days. We found that thrombus resolution
was impaired in the MMP9 -/- þ MMP2 inhibitor with
Fig 1. Thrombus size as measured by weight:length ratio showed larger venous thrombosis (VT) at day 8 in matrix
metalloproteinase (MMP)2 -/-mice (A). Thrombus channelswere fewer inMMP2-/-mice comparedwithwild type (WT)
(B). Photomicrographs in WT (C) show numerous channels in periphery of the thrombus. Fewer von Willebrand’s factor
(vWF)þ channelsnoted inMMP2-/-VT (D). At400,arrows mark channels.T,Thrombus;W,wall.White bar¼10mm.
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in VT size in the MMP2/9 double null mice compared
withWT (n¼ 5;P< .05) (Fig 4,A). Evaluating the veinwall
collagen by Sirius red analysis, we found that MMP9 -/- þ
MMP2 inhibitor andMMP2/9 double null mice had three-
to sixfold reduced collagen content in the vein wall (n¼ 4-5;
P < .05) (Fig 4, B, D, E, and F). Consistent with the single
MMP9 -/- or MMP2 -/- phenotypes, we found
a wﬁvefold increase in vein wall monocytes with MMP9
-/-þMMP2 inhibitor and a fourfold increase in monocytes
in the MMP2/9 double null mice compared with WT
(n ¼ 4; P < .05) (Fig 4, C).
We performed a second analysis using only MMP2 -/-
as the control for the MMP9 -/- þ MMP2 inhibitor andMMP2/9 -/- (Fig 4). We found that comparison using
analysis of variance with Bonferroni correction that the
VT size was only signiﬁcantly larger in the MMP9 -/- þ
MMP2 inhibitor group (P < .05) compared with the
MMP2 -/- group. Vein wall collagen content was signiﬁ-
cantly less in both MMP9 -/- þ MMP2 inhibitor and
MMP2/9 -/- compared with MMP2 -/- (P < .001).
Finally, vein wall monocytes were signiﬁcantly greater in
the MMP9 -/- þ MMP2 -/- inhibitor group (P ¼ .03),
but not greater in the MMP2/9 -/- group.
DISCUSSION
Although anticoagulation is effective treatment for
DVT, no speciﬁc therapies are available to target the vascular
Fig 2. A, Vein wall collagen content was less in matrix metalloproteinase (MMP)2 -/- compared with wild type (WT).
Sirius red stained vein wall section of WT (B), contrasting with the thinner and less dense collagen (red) in the MMP2 -/-
vein walls (C). Histologic images at 100. Procollagen I was not altered in the MMP2 -/- vein wall compared with
WT (D), while procollagen III was reduced at 8 days (E). Tropoelastin gene expression was reduced at 8 days in the
MMP2 -/- compared with WT (F). T, Thrombus. *P < .05.
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Remodeling of the extracellular matrix in vessels is mediated
in part by the MMPs,25 and activity has been visualized
in vivo in arterial injury27 and veins after VT.9 Resolving
VT and the vein wall response are associated with MMP2
andMMP9 time dependent activity changes, but their direct
role had not been assessed.6,7 The MMP2 seems most likely
involved with vein wall metabolism given its kinetics and
activities6,25 and thus we focused on this MMP type. In
this study, we demonstrate VT resolution was impaired in
MMP2 -/- mice, and that the post-thrombotic vein is char-
acterized by temporal changes in collagen content, depen-
dent on both MMP2 with associated genetic, cellular, andinﬂammatory changes. These ﬁndings also suggest a complex
interplay of factors that is likely not simply related to collagen
or matrix turnover.24,25
Although not the primary focus of these experiments,
VT resolution was impaired at the mid-timepoint
(8 days) in MMP2 -/- mice. Our data suggest VT resolu-
tion is in part dependent on MMP2 activity, as VTs were
signiﬁcantly larger in MMP2 -/- mice at 8 days. We have
also observed a correlation between concentration of
MMP activity and thrombus resolution in real time
imaging.9 Prior work in our laboratory has also shown
that deletion or inhibition of MMP2 is associated with
impaired thrombus resolution at 4 days,15,18 independent
Fig 3. Vein wall tumor necrosis factor-alpha (TNFa) in matrix metalloproteinase (MMP)2 -/- was less at 2 and 8 days
(A), while interleukin (IL)-1b was reduced at 2 days (B). C, Vein wall active MMP9 activity was increased in MMP2 -/-
mice at 8 days by zymography. D, Vein wall monocytes were increased at 8 days in MMP2 -/- mice compared with wild
type (WT). E-G, Apoptosis as marked by terminal deoxynucleotidyl transferase end labeling (TUNEL) þ green colo-
calized with 40,6-diamidino-2-phenylindole blue staining nuclei showed less medialþ cells at 8 days in the MMP2 -/- vein
wall compared with WT. At 400. T, Thrombus; W, wall; arrows mark þ cells; *P < .05. White measurement bar ¼
10 mm.
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Fig 4. A, Thrombus size was increased at 8 days in matrix metalloproteinase (MMP)9 -/- þMMP2 inhibitor as well as
MMP2/9 -/- double null mice. B, Collagen content was reduced in the MMP9 -/- þ MMP2 inhibitor and the
MMP2/9 -/- double null compared with wild type (WT). C, Monocytes were elevated in MMP9 -/- þ MMP2
inhibition and MMP2/9 double null -/- mice. D-F, Representative photomicrographs of WT, MMP9 -/- þ MMP2
inhibition, and MMP2/9 -/- mice. Histologic images at 100. T, Thrombus; *P < .05 by analysis of variance with
Dunnett multiple comparison test. #P < .05; ###P < .001 by analysis of variance with Bonferonni correction.
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vascularization.8 MMP2 is critical for neovascularization28
and consistent with impaired VT resolution, signiﬁcantly
fewer vWF þ channels in MMP2 -/- thrombi were found.
The lack of MMP2 activity did not affect early thrombus
formation or resolution, probably because the stasis model
mechanism predominates, as well as cellular mediated reso-
lution may be more important at mid to later time-
points.15,29 Other cellular mechanisms independent from
MMP2 exist as the VT sizes were similar at 21 days, sug-
gesting compensatory accelerated resolution in the
MMP2 -/- mice. This observation also underscores the
temporal importance of MMP2 in VT resolution.
Numerous studies have highlighted the role of MMPs
in the response to vascular injury, including VT resolu-
tion.6,25 Matrix metalloproteinases are zinc containing
endoproteinases with multiple targets, including matrix
and nonmatrix substrates.24 In multiple models of tissue
injury, early activation of both MMP2 and MMP9 occurs
prior to the end stage-ﬁbrotic process,25 including our
own model.6 In this study, we demonstrate that loss of
MMP2 is associated with less vein wall collagen at midterm
after the stasis thrombosis injury. Moreover, the addition of
MMP9 deletion was additive, as the MMP2/9 -/- double
null mice or MMP9 -/- with an exogenous MMP2 inhib-
itor had markedly less post-thrombotic vein wall collagen
than the single MMP2 deletion (Fig 4). Consistent with
our ﬁndings is that both MMP2 and/or MMP9 gene dele-
tions are associated with less constrictive ﬁbrosis in direct
and ﬂow mediated arterial injury models.26,30-32 Although
we did not speciﬁcally investigate the MMP2 -/- venous
vascular smooth muscle cell (VSMC) migration potential,
these reports suggest signiﬁcant migration impairment
in vitro. These studies provide an explanation for our
observed phenotype; namely, less collagen production after
injury occurs, possibly because of less VSMC migration and
activation. We acknowledge that we did not speciﬁcally co-
localize collagen production to VSMC and other medial
cells may be important. Lastly, the protection from late
vein wall ﬁbrosis in MMP2 -/- mice was not observed at
21 days post-thrombosis. We have observed this in other
experiments with different genetic deletions and genetic
backgrounds.21 This suggests that other processes that
are not monocyte and MMP dependent mechanisms of
injury predominate at this late timepoint.
In general, the MMPs regulate vessel collagen by
degradation as well as cellular inﬂux and function.24,25
Deletion of MMP2 was associated with decreased gene
expression of procollagen III and tropoelastin in response
to vein wall injury, suggesting less vein wall metabolic turn-
over. Speciﬁcally, the decrease in vein wall collagen in the
MMP2 -/- mice may be directly related to decreased
collagen gene expression and protein translation. More-
over, increased TNFa is associated with ﬁbrosis,33,34 and
was signiﬁcantly decreased in the MMP2 -/- mice. We
did not directly address if any of the cytokines were mech-
anistically involved with vein wall responses, however. It is
unlikely that VSMC were directly affected, as medial cellproliferation was not affected by loss of MMP2, consistent
with some, but not all reports.25,31 However, medial vein
wall cellular apoptosis was signiﬁcantly decreased in
MMP2 -/- compared with WT. This may be related to
the relative increase in MMP9 activity in the MMP2 -/-
mice, and greater clearance of apoptotic cells, as suggested
in other models.12 Other MMPs that we did not assess may
also play a role in response to injury, such as MMP3
and MMP12.32 Besides the proinﬂammatory cytokine
induction of MMP activation, vessel wall strain may
contribute as has been highlighted by arterial experimental
data.35 Certainly, stasis thrombosis distends the vein wall
and likely directly promotes MMP activation, possibly
accounting for the upregulation of MMP9 activity in the
MMP2 -/- mice.
Although TIMPs may play a major role in certain
disease process such as atherosclerosis36 and hepatic
ﬁbrosis,37 it did not appear these were altered signiﬁcantly
in our prior report after stasis VT.6 Preliminary experiments
with TIMP1 -/- mice, which have signiﬁcantly increased
MMP2 and 9 activities at 8 and 21 days, did not show
a signiﬁcant increase in vein wall collagen (Henke PK,
unpublished data). This suggests that increased MMP2
and 9 activity itself does not worsen parameters of vein
wall healing in the stasis VT model, contrasting with solid
organ injury models.37
Most of the phenotype differences were observed
8 days post-VT, which is when monocytes predominate in
the vein wall.5,14,15 While part of the normal inﬂammatory
response, monocytes may or may not promote ﬁbrotic
tissue repair.38 Consistent with the current report is that
P-selectin inhibition after stasis VT is associated with
increased vein wall monocytes, but less vein wall
ﬁbrosis.22,39 Recent investigations suggest that monocyte
subtypes confer differing inﬂammatory or anti-
inﬂammatory responses (eg, M2) depending on the envi-
ronment and time frame.38 Interestingly, both MMP2 -/-,
the MMP9 -/- þ MMP2 inhibitor, and the double null
mice had increased vein wall monocyte inﬂux, suggesting
these proteinases are not essential for monocyte inﬂux
following injury but may be important for cellular egress.
Indeed, in a pulmonary inﬂammatory model with
MMP2/9 double deletion, a signiﬁcant increase in inﬂam-
matory cells was observed after injury because of inhibited
trafﬁcking.12 Another mechanism accounting for increased
monocytes may involve MMP chemokine processing.24
However, since MCP-1 was not signiﬁcantly altered with
MMP2 deletion, other chemokines such as MCP 2-5
may be responsible for the increase in vein wall monocytes
observed. Interestingly, the MMP9 -/- þMMP2 inhibitor
had a more exaggerated response with larger thrombi and
more vein wall monocytes than the MMP2/9 -/-
compared with MMP2 -/- alone. This may be due to the
fact that the MMP2 inhibitor, while speciﬁc,17 may have
other effects on the vein wall injury as it is a long chain fatty
acid with ﬁbronectin binding sites, and may mimic the
basement membrane of the vessel wall with alteration in
monocyte inﬂux and thrombus resolution.40
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models of cardiovascular injury and VT.11,25,41 Although
the deletion of MMP2 in these experiments correlates
with diminished collagen at 8 days, the signiﬁcance of
this effect is lost by 21 days. Thus, the role of MMP2 in
the ﬁbrotic response is temporally related to the duration
of thrombus contact. Translationally, the timing and
duration of MMP2 inhibition needs to guide future studies
in treatment of PTS, and a practical means to reduce
up-regulation of MMPs may be by limiting the thrombus-
vein wall contact time via anticoagulation and pharmaco-
mechanical therapies.4 More importantly, the cost of
decreased ﬁbrosis may be a larger thrombus.AUTHOR CONTRIBUTIONS
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Supplementary Fig 1 (online only). Representative polarized photomicrographs of Sirius red stained nonthrombosed
vein, and 2, 8, and 21 days thrombosed inferior vena cava (IVC) sections. Collagen is white. Note vein wall thickening
over time after thrombosis. The arrows demarcate the vein wall. T, Thrombus.
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Supplementary Fig 2 (online only). Photomicrographs of 8 days hematoxylin and eosin (H&E) stained thrombosed
inferior vena cava (IVC) sections in wild type (WT) and in matrix metalloproteinase (MMP)2 -/- mice. Higher-power
views show medial and intimal layers of the vein wall. Note no difference in intimal layers as denoted by the arrow.
T, Thrombus.
Supplementary Fig 3 (online only). Representative panels of wild type (WT)C57 andC57 inmatrixmetalloproteinase
(MMP)2 -/- at 400. Arrows denote þMac2 cells. Fewer are present in the WT vein wall. T, Thrombus;W, wall.
JOURNAL OF VASCULAR SURGERY
1384.e2 Deatrick et al November 2013
